Intellia Therapeutics NTLA Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's change in deferred revenue?
- Intellia Therapeutics (NTLA) reported change in deferred revenue of -$6.66M in Q1 2026.
- How has Intellia Therapeutics's change in deferred revenue changed year-over-year?
- Intellia Therapeutics's change in deferred revenue decreased by 30.7% year-over-year, from -$5.1M to -$6.66M.
- What is the long-term trend for Intellia Therapeutics's change in deferred revenue?
- Over 3 years (2021 to 2025), Intellia Therapeutics's change in deferred revenue has grown at a -3.6% compound annual growth rate (CAGR), from -$31.36M to -$28.11M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.